2021 in Review and What ’ s Next
11
What ’ s Next for LRRK2
+ Prevention on the horizon : MJFF ’ s landmark study PPMI ( read more on page 16 ) is expected to recruit LRRK2 mutation carriers with and without Parkinson ’ s throughout 2022 and 2023 . Learnings from studying these individuals are considered critical for LRRK2 therapies to move into preventive trials .
+ A revolution in Parkinson ’ s genetics : Intense study of LRRK2 requires MJFF to financially support an ongoing campaign to identify other cellular players with roles in the LRRK2 pathway that gives rise to Parkinson ’ s . In 2021 , Foundation-supported research uncovered another gene , CORO1C , that may increase likelihood of Parkinson ’ s in conjunction with a LRRK2 mutation . In 2022 , Foundation grantees will continue to study this emerging genetic target and its potential for drug development .